<DOC>
	<DOCNO>NCT01093729</DOCNO>
	<brief_summary>Study Design : Randomized , double-blind , placebo-controlled , escalate single-dose design . Five ascend dose cohort plan .</brief_summary>
	<brief_title>A Study HM11260C Healthy Male Subject</brief_title>
	<detailed_description>Primary Objective : To assess safety , tolerability , pharmacokinetics pharmacodynamics single subcutaneous dose HM11260C healthy male subject .</detailed_description>
	<criteria>1 . Healthy male volunteer , age range 20 45 year 2 . Weight &gt; 50 &lt; 90kg , Body mass index &gt; 18 &lt; 27 Subject inform investigational nature study voluntarily agree participate study Exclusion Criteria 1 . Acute disease within 1 month prior start study drug administration 2 . Has previously disease affect drug absorption , distribution , metabolism , excretion ( e.g. , inflammatory gastric disease , gastric intestinal ulcer , hepatic disease , renal disease ) 3 . History presence clinically significant active cardiovascular , pulmonary , renal , endocrine , hematological , gastrointestinal , central nervous system , psychiatric disorder , autoimmune disease , malignant tumor 4 . Has unsuitable clinical test result medical checkup , within 35 day prior start administration study drug ( medical history , physical examination , ECG , laboratory test ) 5 . Laboratory test result 1 . AST ( sGOT ) ALT ( sGPT ) &gt; 1.25Xupper normal limit 2 . Total bilirubin &gt; 1.5Xupper normal limit 3 . Absolute Neutrophil Count &lt; 1500 mm2 6 . History presence clinically significant allergic disease ( include mild allergic rhinitis allergic dermatitis necessary medication ) 7 . Prior exposure product relate Exenatide 8 . Use prescription medication within 14 day prior Day 1 9 . Use medication within 7 day prior Day 1 ( overthecounter medication , herbal product , nutrient , vitamin ) 10 . Subject ca n't eat standard meal receive Korea University Anam Hospital 11 . Donor whole blood transfusion within 60 day prior start study drug administration donor apheresis within 20 day Receiver blood transfusion within 1 month 12 . Participation another clinical study within 60 day prior start study drug administration 13 . Taking Caffein ( &gt; 5cups/ day ) alcohol abuse ( &gt; 30g/ day ) excessive smoker ( &gt; 10 Subject inform investigational nature study voluntarily agree participate study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Exendin-4</keyword>
</DOC>